Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial
Keywords:
Cholinergic urticaria
Omalizumab
Clinical trial
Exercise
Exercise challenge test
Cholinergic urticaria
UCOL score
Editorial note:
© 2019 American Academy of Allergy, Asthma & Immunology
Citation:
Sabaté-Brescó, M. (Marina); Gastaminza, G. (Gabriel); Azofra, J. (Julián); et al. "Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial". The Journal of Allergy and Clinical Immunology: In Practice. 7 (5), 2019, 1599 - 1609
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.